It is not clear whether eradication of Helicobacter pylori infection reduces the risk for metachronous gastric carcinoma.
Dr Sang Gyun Kim and colleagues from South Korea performed a prospective, randomized, open-label trial of the effects of H pylori eradication on the incidence of metachronous carcinoma after endoscopic resection of gastric tumors.
From 2005 through 2011 there were 901 consecutive patients with H pylori infection who had been treated with endoscopic resection for gastric dysplasia or cancer, and who were assigned randomly to groups given therapy to eradicate the infection or no therapy.
The eradication group received 20 mg omeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 1 week.
|10 patients who received H pylori eradication developed metachronous carcinoma|
|Clinical Gastroenterology & Hepatology|
The team reported that patients underwent endoscopic examination 3, 6, and 12 months after treatment, and then yearly thereafter.
The researchers' primary outcome was development of metachronous gastric carcinoma.
During a median follow-up period of 3 years, 10 patients who received H pylori eradication, and 17 controls developed metachronous carcinoma, but this difference was not significant.
The team found that the incidence of metachronous carcinoma between the 2 groups did not differ significantly at 1, 2, 3, and 4 years after administration of the therapy.
The research team observed no significant differences in the development of metachronous carcinoma among patients who were positive or negative for H pylori infection.
Dr Kim's team concludes, "In this prospective trial, eradication of H pylori after endoscopic resection of gastric tumors did not significantly reduce the incidence of metachronous gastric carcinoma."